NanoVibronix, Inc.
NanoVibronix, Inc. (NAOV) Stock Overview
Explore NanoVibronix, Inc.’s financial performance, market position, analyst ratings, and future outlook.
NAOV Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of NanoVibronix, Inc. (NAOV) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $5.94.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.14 and a market capitalization of 3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Brian M. Murphy
31
525 Executive Boulevard, Elmsford, NY
2015